ImmunoGen (NASDAQ:IMGN) will be releasing its earnings data before the market opens on Friday, November 2nd. Analysts expect ImmunoGen to post earnings of ($0.30) per share for the quarter.
ImmunoGen stock opened at $5.43 on Thursday. ImmunoGen has a 12-month low of $4.80 and a 12-month high of $13.41. The firm has a market cap of $877.74 million, a P/E ratio of -7.24 and a beta of 1.96. The company has a current ratio of 5.76, a quick ratio of 5.73 and a debt-to-equity ratio of 0.02.
Several research firms recently issued reports on IMGN. ValuEngine raised shares of ImmunoGen from a “hold” rating to a “buy” rating in a research note on Wednesday, October 17th. BidaskClub raised shares of ImmunoGen from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 14th. William Blair reaffirmed an “outperform” rating on shares of ImmunoGen in a research note on Monday, October 22nd. Zacks Investment Research downgraded shares of ImmunoGen from a “hold” rating to a “sell” rating in a research note on Thursday, August 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of ImmunoGen in a research report on Monday, July 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. ImmunoGen has a consensus rating of “Buy” and a consensus target price of $14.75.
ImmunoGen Company Profile
ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.
Featured Story: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.